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Abstract
Objectives: The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by
Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to identify
possible early markers of loss of ambulation.
Methods: One hundred and thirteen patients (age range 4.1–17, mean 8.2) fulfilled the inclusion criteria, 67 of the 113 were
on daily and 40 on intermittent steroids, while 6 were not on steroids. All were assessed using the 6 Minute Walk Test
(6MWT), the North Star Ambulatory Assessment (NSAA) and timed test.
Results: On the 6MWT there was an average overall decline of222.7 (SD 81.0) in the first year and of264.7 (SD 123.1) in the
second year. On the NSAA the average overall decline was of 21.86 (SD 4.21) in the first year and of 22.98 (SD 5.19) in the
second year. Fourteen children lost ambulation, one in the first year and the other 13 in the second year of the study. A
distance of at least 330 meters on the 6MWT, or a NSAA score of 18 at baseline reduced significantly the risk of losing
ambulation within 2 years.
Conclusions: These results can be of help at the time of using inclusion criteria for a study in ambulant patients in order to
minimize the risk of patients who may lose ambulation within the time of the trial.
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Introduction
In the last few years the increasing number of potentially
effective therapeutical approaches for patients affected by
Duchenne muscular dystrophy (DMD) has stimulated the interest
in outcome measures to be used in clinical trials. The 6 minute
walk test (6MWT) has been recently chosen as the primary
outcome measure as it provides a global assessment of functional
mobility, endurance, and ability to walk. Its use has been reported
in international multicenter clinical trials and longitudinal natural
history studies in DMD ambulant patients [1,2,3,4]. Functional
scales, such as the North Star Ambulatory Assessment (NSAA)
represent an ideal additional tool to the 6MWT, as they provide
information on a wider spectrum of functions that reflect everyday
life activities [5]. The NSAA has been specifically developed for
ambulant DMD boys and has also been validated and used in
multicentric longitudinal studies [3,4,6,7,8].
We have recently reported data from a multicentric longitudinal
study, describing the changes on both 6MWT and NSAA
observed over 12 months in ambulant DMD boys.
In the present study we report the results at 24 months using the
same assessments. The aim of the study was to assess the spectrum
of changes over 24 months in the individual measures and their
correlation with age and possible treatment with steroids. We were
also interested to establish the difference between the first and the
second year results in the cohort and whether, given a longer
follow up, we could identify early markers of events such as loss of
ambulation.
Subjects and Methods
The study is a longitudinal multicentric cohort study involving
11 tertiary neuromuscular centers in Italy. Patients were recruited
between January 2008 and June 2009 and followed for at least two
years with the last follow up visit performed in July 2011. The
study was approved by the Ethical Committee of each centre.
Patient inclusion criteria at baseline were: genetically proven
DMD diagnosis, patient still ambulant and able to walk
independently for at least 75 meters, no severe or moderate
learning difficulties or behavioral problems. Genetic and treatment
information were collected and classified following the criteria
used in our previous study [4]. All patients attending the 11
participating centers who fulfilled the inclusion criteria were
enrolled in the study. As part of the routine assessments in all
centers patients are seen at least once every 12 months and all
centers performed at each visit the NSAA followed by the 6MWT.
Data were collected from the first assessment after recruitment
(baseline) from the 12 month and the 24 month follow up
assessment.
As the various centers used different types of steroids
(deflazacort and prednisone) and had different regimes, we
broadly subdivided our cohort into: a) no steroids: this included
boys who had never been on steroids and others who had used
them for less than a year and had stopped treatment at least one
year before the study; b) intermittent regime, patients who had
been, at the time of the study, on alternate days or alternate weeks
or 10 days on/10 days off of either .75 mg of prednisone or
.9 mg/kg/day of deflazacort for at least a year; c) daily regime,
patients who had been, at the time of the study, on daily treatment
of .75 mg of prednisone or .9 mg/kg/day of deflazacort for over a
year, also including those in whom the dose had not been always
completely adjusted to the current weight. A small number of
patients who took deflazacort on alternate days but with a dose of
approximately 2 mg/kg were also included in this group as their
monthly dose was similar if not higher to those with a standard
daily dose of steroids.
Details of the training for the physiotherapists involved in the
study and of the interobserver reliability for NSAA among the
centers have already been reported [3,4,6].
Standard Protocol Approvals, Registrations, and Patient
Consents
As this was an observational study, requiring non invasive
procedures of assessment that were used routinely in all centers
and did not require extra visits to the centres, no informed consent
was required as the data were analyzed anonymously. Parents of
participants (all our patients were minor/children) and patients
were informed that the data collected as part of our routine clinical
assessment were going to be used anonymously for an observa-
tional study defining natural history of the diseases and they all
gave verbal consent. Written consent was not required as the data
were analyzed anonymously. The Ethical committee from
Catholic University, Rome approved this procedure. All clinical
investigation was conducted according to the principles expressed
in the Declaration of Helsinki.
6MWT
6MWT was performed in all DMD ambulant boys older than 5
according to the ATS guidelines [9], modified by having two
examiners, one recording time and distances and one staying close
to the patient for safety issues.
NSAA
The scale consists of 17 items, ranging from standing (item 1) to
running (item 17) and includes several items assessing abilities that
are necessary to remain functionally ambulant, items assessing
abilities, such as head raise and standing on heels that can be
partly present in the early stages of the disease and a number of
activities such as hopping, or running that are generally never fully
achieved in untreated DMD boys but that have been found in
those treated with daily steroids.
Each item can be scored on a 3 point scale using simple criteria:
2 -Normal achieves goal without any assistance; 1 -Modified
method but achieves goal independent of physical assistance from
another person; 0 - Unable to achieve independently.
A total score can be achieved by summing the scores for all the
individual items. The score can range from 0, if all the activities
are failed, to 34, if all the activities are achieved.
Timed Items
The NSAA also includes the possibility to record timed items
(10 meter timed walk/run test and time to rise from the floor or
Gower test) [6,8]. The time taken to complete the task is not part of
the global score but provides an additional measure of the DMD
boys’ abilities that can be monitored over time. The 10 meter
timed test is usually expressed as the time spent for walking/
running 10 meters. As in children who are or become unable to
perform this task the time cannot be measured, conventionally a
time equal or bigger than the worst performance in the group is
subjectively given to indicate poor performance.
Statistical Analysis
Functional scales were evaluated longitudinally over a 24
months period of time. The dependence of NSAA, 6MWT, 10 m
and Gowers test on time was evaluates using a mixed random
effect model, adjusting for baseline age (,=7 vs.7 years) and the
use of steroids at baseline (alternate vs continuous). The age of 7
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was chosen according to our previous findings showing that 7
years appear to be the age when DMD boys have a slope of
deterioration [4] and to identical results in other cohorts [5].
Correlations were evaluated by the Spermann rank correlation
coefficients.
The effect of baseline assessments on the risk to become unable
to walk was evaluated by a Receiver operating characteristic
(ROC) analysis that indicates the cut-off value maximizing at the
same time the sensitivity and the specificity of that variable.: For
each baseline variable the cut-off value better indicating an
increase in the risk of loss of the ambulation ability was
determined.
Logistic univariate analysis were used to estimate the impact of
each baseline factor on the risk of loss of ambulation.
Results
One hundred and thirteen patients fulfilled the inclusion criteria
and entered the study.
Ninety-six of these patients have already been reported in our
previous study reporting 12 month follow up in 106 ambulant
DMD boys [4]. Six of the 106 were lost at follow up, three entered
a stem cell study and one died. Seventeen new patients who were
recruited using the same protocol and had not completed the 12
month assessment at the time of the first study were added to the
present study. All the tests were performed safely without any
mayor fall during the performance of the individual measures. Of
the 113 boys, 67 were on daily (mean age 8,5) and 40 on
intermittent steroids (mean age 7,8), and 6 were not on steroids
(mean age 6,9).
6MWT
Three children lost the ability to perform the test within 1 year
and another 13 within 2 years from baseline (table 1). The 6MWD
showed an average overall decline of 222.7 (SD 81.0) meters in
the first year and of 264.7 (SD 123.1) in the second year.
The changes were significantly different in the two baseline age
groups (test for interaction, p,0.001): children below 7 remained
on the average stable with also a slight increase during the first
year (mean 6MWT change= +18.7 (SD=71.4)) and also during
the second year (mean 6MWT change= +14.6 (SD=67.3)).
Children above 7 had a decrease of about 42 meters during the
first year (mean 6MWT change=241.8, SD=78.3) and about 80
meters during the second year (mean 6MWT change=280.6,
SD=96.7) (Figure 1).
The changes were not significantly different according to steroid
treatment (alternate vs continuous) (p for interaction= ns).
NSAA
One child lost the ability to perform the test within 1 year and
another 8 within 2 years from baseline (table 1). There was an
average overall decline of 21.86 (SD 4.21) in the first year and of
22.98 (SD 5.19) in the second year.
The changes were significantly different in the two baseline age
groups (test for interaction, p,0.001): children below 7 remained
on the average stable during the first year (mean NSAA
Figure 1. Mean changes in 6MWT and in NSAA scores in patients below the age of 7 years at baseline (grey line) and above (black
line).
doi:10.1371/journal.pone.0052512.g001
Table 1. Details of number of patients who lost the ability to
perform the individual tests at baseline, 12 and 24 months.
BASELINE 1 YEAR 2 YEARS
GOWERS TEST 8 16 34
6MWT 0 3 16
10 m 0 1 13
NSAA 0 1 9
Loss of ambulation 0 1 13
doi:10.1371/journal.pone.0052512.t001
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change =+0.15 (SD=4.8)) and started to decrease during the
second year (mean NSAA change=20.78 (SD=5.1)). Children
above 7 had a decrease of about 3 points during the first year
(mean NSAA change=23.0, SD=3.3) and higher than 4 points
during the second year (mean NSAA change=24.2, SD=4.8)
(Figure 1).
Timed Items
Eight children were unable to perform the Gower test at
baseline. Other 8 lost the ability to perform it within 1 year and
and another 18 within 2 years. The changes in the time taken to
perform the manoeuvre in the subjects who were still able to
perform it showed an average overall decline of 5.05 seconds (SD
12.45) in the first year and of 7.83 (SD 16.01) in the second year.
The changes were significantly different in the two baseline age
groups (test for interaction, p = 0.003): children below 7 had a
mean decrease of 1.75 seconds during the first year (SD=4.62)
and of 1.79 sec during the second year (SD=7.33). Children
above 7 had a decrease of 6.88 seconds during the first year
(SD=14.87) and of 11.32 during the second years (SD=18.59).
During the first year only 1 child lost the ability to walk (i.e not
being able to take more than 5 steps) and to perform all tests. In
the second year another 12 children lost ambulation. Nine where
unable to perform any test while other 5 were unable to perform
Figure 2. Risk of losing ambulation within 2 years in relation to different cut-off points of 6MWD and NSAA scores at baseline.
doi:10.1371/journal.pone.0052512.g002
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6MWT and timed tests but were still able to perform some items
on the NSAA (Table 1).
Factors Predicting the Probability of Loss of Ambulation
after 2 Years
Cut-off values for each baseline variable giving the maximum
sensitivity and specificity were estimated from the ROC curves:
the NSAA value best discriminating patients at high risk of
ambulation loss was 22, the best 6MWD cut-off was 330 m, the
best 10 m cut-off was 7 sec and the best cut-off for the Gowers
assessment was 7.2 sec. In Table 2 the association between
baseline variables value (above and below the optimized cut-off
values) are reported. All the children who lost ambulation were
older than 7. Figure 2 shows the risk of losing ambulation within 2
years using different cut off points for 6MWT and NSAA.
Discussion
The aim of the study was to assess the spectrum of changes over
24 months using a combined approach including a measure of
endurance (6MWT), a functional scale (NSAA) and timed tests in a
large cohort of 113 ambulant DMD boys of age ranging between
4.1 and 17 years at baseline. All tests were well tolerated and easily
administered and were safely completed.
Our results showed that the changes in 6MWD were of
287.3 m over 24 months, with a much higher change in the
second year compared to the first one. There was a substantial
heterogeneity with a SD of 123.1. Similar results were obtained in
the NSAA with a mean change of approximately 25 points over
24 months, and a SD of 5.19.
As previously reported for the 12 month assessment [4], the
changes were different according to age. Boys who were below the
age of 7 at baseline had some improvement on both NSAA and
6MWT in the first year and, a small improvement on 6MWT was
also found in the second year.
Those above the age of 7 in contrast showed a progressive
deterioration that was much more obvious in the second year on
all tests. Adding an extra year in this age group had a significantly
higher impact on motor performance and increased the chances of
losing ambulation.
It has recently been reported that the improved distances on the
6MWT in the younger boys should be considered the result of
growth rather than a real improvement of muscle function,
suggesting the use of a % predicted 6MWD calculated using an
age and height-based equation that would account for growth and
development [2]. Unfortunately in our study height measures were
not standardized across centers as this was not planned at the time
when the study started and we therefore cannot provide further
evidence of the value of this analysis.
When we assessed the possible effect of steroids on changes over
24 months we could not confirm our previous findings obtained at
12 months suggesting a positive effect of daily steroids on the
outcome measures [4]. On the 24 month analysis the magnitude of
changes in the overall group of patients with daily regime was not
significantly different than in those with intermittent regime. The
similar decline between patients with daily and intermittent
steroids may be explained by the fact that the study was not
designed to establish the effect of steroids and the groups were not
stratified according to their steroid regime or age. With few
exceptions, the patients who were able to walk beyond the age of
10 and all above the age of 12 were on daily steroids and the group
on daily treatment was on average one year older than those on
intermittent regime and therefore at higher risk of sudden
deterioration. This should therefore be further explored with
prospective studies with appropriate stratification and randomiza-
tion according to age and steroid regime.
In agreement with previous studies we also observed that the
ability to performed Gowers test was lost before boys failed the
other tests [10], with eight boys already unable to get up from the
floor at baseline, at the time when they were still able to walk at
least 75 meters. The number of patients failing this ability
progressively increased at 12 and 24 months, followed by the
inability to perform the 6MWT, and in a smaller number of
patients by the 10 meters timed test. As the NSAA also includes
activities such as lifting head or standing that can be retained even
after loss of ambulation, there were a number of patients in whom
NSAA scores could be recorded even after they were unable to
perform all the other tests. Additional measures, such as those
assessing upper limb activities, could have helped to follow possible
changes of other functional abilities after loss of ambulation.
We were also interested to establish whether we could identify
cut off points able to predict loss of ambulation or, conversely to
define a cohort with a low risk of losing ambulation within two
years. This information appears to be useful at the time of
recruiting DMD boys in a clinical trial in which the primary
outcome measures is the 6MWT that can only be performed in
ambulant patients.
While only one boy lost ambulation at one year from baseline,
another 12 lost the ability in the second year. The analysis of our
results suggested that a 6MWD of at least 330 meters, or a NSAA
score of 18 reduced significantly the risk of losing ambulation
within 2 years. The same applied to walking ten meters within 7
seconds or getting up from the floor within 10 seconds. These
results can be of help at the time of using inclusion criteria for a
study in ambulant patients in order to minimize the risk of patients
who may lose ambulation within the time of the trial.
This study provides for the first time longitudinal data using
6MWT, a functional scale and timed items over a 24 month
period, providing the spectrum of changes observed in each
measure and predictors of loss of ambulation. In our cohort one
extra year produced a significant difference in the performance
and in the standard deviations of the changes on all measures. Age
Table 2. Association between baseline variables value (above
and below the optimized cut-off values).
OR 95.0% C.I. P value
Lower Upper
NSAA baseline
,= 22 ref
.22 37.5 4.7 300.4 0.001
6MWT baseline
,= 330 ref
.330 23.6 4.9 113.8 ,0.001
Gowers baseline
.7.2 ref
,= 7.2 6.2 1.6 23.6 0.007
10 m baseline
.7 ref
,= 7 7.9 2.2 28.3 0.002
All the children who lost ambulation were older than 7.
doi:10.1371/journal.pone.0052512.t002
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and scores at baseline will help to identify the children who will
lose ambulation or are more likely to show steep changes in their
performance and these aspects should be considered at the time of
designing a clinical trial.
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